Efficacy and safety of infliximab biosimilar Inflectra® in severe sarcoidosis
| Autor: | Frouke T. van Beek, Marcel Veltkamp, Milou C. Schimmelpennink, Adriane D.M. Vorselaars, Ruth G.M. Keijsers, Heleen A. Crommelin, Vera H.M. Deneer |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty business.industry Retrospective cohort study Biosimilar medicine.disease Gastroenterology Infliximab Pulmonary function testing 03 medical and health sciences 0302 clinical medicine Biosimilar Pharmaceuticals 030228 respiratory system Tolerability Refractory Internal medicine medicine 030212 general & internal medicine Sarcoidosis business medicine.drug |
| Zdroj: | Respiratory Medicine. 138:S7-S13 |
| ISSN: | 0954-6111 |
| Popis: | Background Infliximab, a monoclonal antibody against tumor necrosis factor alpha (TNF-α) is effective third-line therapy in severe sarcoidosis. The originator product of Infliximab, Remicade®, is expensive, limiting universal access. Recently, a less expensive biosimilar of infliximab, Inflectra®, has become available, but the efficacy and tolerability has not been studied in sarcoidosis. Methods In this retrospective cohort study, 29 patients treated with the infliximab biosimilar Inflectra®, were analysed. Patients received Inflectra® intravenously monthly at a dose of 5 mg/kg. We measured trough levels before every infusion. Before and after 6 months of induction therapy pulmonary function and disease activity were evaluated using Standardised Uptake Value (SUV) of the 18F-fluorodeoxyglucose by positron emission tomography (18F-FDG PET), soluble interleukin-2 receptor (sIL-2R), angiotensin converting enzyme (ACE) and health-related quality of life (HRQOL). Results In patients with pulmonary sarcoidosis as main treatment indication (n = 15) the predicted FVC improved with 8.1%, p Conclusion Infliximab biosimilar Inflectra® seems effective in the treatment of refractory sarcoidosis with a comparable safety profile to the reference product Remicade®. Inflectra® can be considered as an alternative and less expensive option for patients with refractory sarcoidosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect